5727891
Last Update Posted: 2024-12-19
Recruiting has ended
All Genders accepted | 18 Years + |
128 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Evaluation of Tonabersat for DME
This randomized clinical trial will evaluate the effect of tonabersat compared with placebo on central subfield thickness (CST) in eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity.
The primary objective is to assess the effects of tonabersat, an orally administered Connexin43 hemichannel inhibitor, on central subfield thickness (mean change) compared with placebo in eyes with CI-DME and good visual acuity at 6 months.
Exploratory objectives will evaluate biomarkers of kidney function for potential benefit. Furthermore, this phase 2 study is being conducted to determine whether the conduct of a phase 3 trial has merit and provide information on outcome measures needed to design a phase 3 trial.
Eligibility
Relevant conditions:
Diabetic Macular Edema
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Cynthia Stockdale, MSPH
DRCRNET@JAEB.ORG
8139758690
Data sourced from ClinicalTrials.gov